Biocytogen, Whitehawk Therapeutics team up on bispecific antibody-drug conjugate development

Whitehawk Therapeutics

Whitehawk Therapeutics

WHWK

0.00
  • Whitehawk Therapeutics entered a global collaboration with Biocytogen to develop bispecific antibody-drug conjugates for oncology.
  • Biocytogen will supply up to five fully human bispecific antibodies from its RenLite platform for evaluation with Whitehawk’s ADC linker-payload technologies.
  • Whitehawk holds an option to advance resulting BsADC candidates, taking global rights and full program control if exercised.
  • Biocytogen will receive an upfront payment, milestones tied to development, regulatory and commercial events, and low single-digit royalties on net sales.
  • Whitehawk targets new ADC IND filings within 12-24 months, using the collaboration to expand its pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.